secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950170-23-004085
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis reports Q4 2022 revenue $16.7M, net loss $31.1M; guides FY2023 revenue $68-72M
--------------------------------------------------------------------------------

- Q4 2022 revenue $16.7M, full year $65.0M; net loss Q4 $31.1M ($0.67/share), full year $113.3M ($2.48/share).
- Cash and investments $167.7M at Dec 31, 2022; FY2023 cash usage guided to ~$75M, down from $119M in 2022.
- Partnership with Moderna for genomic testing in personalized cancer vaccine trials; MRD validation study with Criterium and ABRCC.
- Strategic review completed; new focus on MRD, personalized cancer vaccines, and pharma clinical trial support.
- FY2023 net loss guided to ~$103M, improved from $113M in 2022 due to headcount reduction savings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000095017023004085/0000950170-23-004085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000095017023004085/psnl-20230223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer